• Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live
• Tradename: M-M-R II
• Manufacturer: Merck & Co., Inc.
• Vaccine Ontology ID: VO_0000069
• CDC CVX code: 03
• Type: Live, attenuated vaccine
• Status: Licensed
• Location Licensed: USA(License #0002), Canada
• Host Species for Licensed Use: Human
• Allergen: Gelatin, Neomycin, Eggs
• Preparation: The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests (FDA: MMR-II).
• Immunization Route: subcutaneous injection
• Storage: 2 to 8°C (36 to 46°F) or colder. Do not freeze.
• Approved Age for Licensed Use: 12 months or older
• Contraindication: Hypersensitivity to any component of the vaccine, a history of anaphylactic or anaphylactoid reactions to neomycin (FDA: MMR-II).
• Description: M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX* (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jeryl Lynn** (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX* II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts (FDA: MMR-II).

Human Response

• Immune Response: Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination (FDA: MMR-II).
• Side Effects: Side effects of vaccination are: fever, headache, dizziness, and irritability.
• Efficacy: Many clinical studies have shown the vaccine have a high rate of efficacy protection after vaccination with MMR-II (FDA: MMR-II).